IP Verse

Arrow Generiques / Puren Pharma Gmbh & Co Kg competitive analysis

Latest oppositions filed by Arrow Generiques / Puren Pharma Gmbh & Co Kg

Explore patent oppositions filed by Arrow Generiques / Puren Pharma Gmbh & Co Kg against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Aug 27, 2026
Patent NumberTitleApplicantOpposition Date
EP3578175
Rapid Dissolution Formulation Of A Calcium Receptor-Active CompoundAMGENAug 29, 2023
EP3342411
Rapamycin Derivative For Treating Pancreas CancerNOVARTISJun 1, 2020
EP3351246
Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated AngiogenesisNOVARTISFeb 24, 2020

Latest PTAB cases involving Arrow Generiques / Puren Pharma Gmbh & Co Kg

Discover the latest PTAB cases involving Arrow Generiques / Puren Pharma Gmbh & Co Kg, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Arrow Generiques / Puren Pharma Gmbh & Co Kg with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Aug 27, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ARROW GENERIQUES PUREN PHARMA1 - - -
AMGEN9146811